Searched for: Department/Unit:Cell Biology
Dual inhibition of TNF-α and IL-1β signaling through BIG2 ameliorates osteoarthritis in mouse and primate models
Fu, Wenyu; Liu, Ronghan; Wo, Jin; Liu, Xin; Wang, Shuya; Song, Wenhao; Zhu, Haoran; Cui, Yazhou; Chen, Yuehong; Wang, Chao; Zhang, Lei; Schwarzkopf, Ran; Oh, Irvin; Wiznia, Daniel H; Sun, Guodong; Liu, Chuan-Ju
Osteoarthritis (OA), a leading cause of disability, is characterized by chronic low-grade inflammation and metabolic dysregulation in chondrocytes. TNF-α and IL-1β are key inflammatory drivers in OA pathogenesis, but clinical trials targeting them individually have been unsuccessful, highlighting the potential need for dual-targeting strategies. By screening a US Food and Drug Administration-approved drug library, we identified dabigatran, a thrombin inhibitor, as a potent dual suppressor of TNF-α and IL-1β signaling that restored chondrocyte metabolism. In preclinical OA models, including both mice and cynomolgus macaques, dabigatran attenuated cartilage degeneration, alleviated pain, and improved joint function. To elucidate the molecular mechanisms, we performed biochemical copurification coupled with mass spectrometry, identifying brefeldin A-inhibited guanine nucleotide-exchange protein 2 (BIG2) as a previously unknown dabigatran-binding target. Mechanistically, dabigatran binds to BIG2, promoting BIG2-dependent TNFR1 release to dampen TNF-α signaling while enhancing BIG2-mediated IL-1R1 degradation through the autophagy-lysosome pathway to limit IL-1β effects. These findings establish BIG2-mediated receptor trafficking and membrane dynamics as a regulatory node that concurrently inhibits TNF-α and IL-1β signaling, suggesting this pathway as a potential therapeutic strategy for OA.
PMID: 43013683
ISSN: 1946-6242
CID: 6075825
Dual inhibition of TNF-α and IL-1β signaling through BIG2 ameliorates osteoarthritis in mouse and primate models
Fu, Wenyu; Liu, Ronghan; Wo, Jin; Liu, Xin; Wang, Shuya; Song, Wenhao; Zhu, Haoran; Cui, Yazhou; Chen, Yuehong; Wang, Chao; Zhang, Lei; Schwarzkopf, Ran; Oh, Irvin; Wiznia, Daniel H; Sun, Guodong; Liu, Chuan-Ju
Osteoarthritis (OA), a leading cause of disability, is characterized by chronic low-grade inflammation and metabolic dysregulation in chondrocytes. TNF-α and IL-1β are key inflammatory drivers in OA pathogenesis, but clinical trials targeting them individually have been unsuccessful, highlighting the potential need for dual-targeting strategies. By screening a US Food and Drug Administration-approved drug library, we identified dabigatran, a thrombin inhibitor, as a potent dual suppressor of TNF-α and IL-1β signaling that restored chondrocyte metabolism. In preclinical OA models, including both mice and cynomolgus macaques, dabigatran attenuated cartilage degeneration, alleviated pain, and improved joint function. To elucidate the molecular mechanisms, we performed biochemical copurification coupled with mass spectrometry, identifying brefeldin A-inhibited guanine nucleotide-exchange protein 2 (BIG2) as a previously unknown dabigatran-binding target. Mechanistically, dabigatran binds to BIG2, promoting BIG2-dependent TNFR1 release to dampen TNF-α signaling while enhancing BIG2-mediated IL-1R1 degradation through the autophagy-lysosome pathway to limit IL-1β effects. These findings establish BIG2-mediated receptor trafficking and membrane dynamics as a regulatory node that concurrently inhibits TNF-α and IL-1β signaling, suggesting this pathway as a potential therapeutic strategy for OA.
PMID: 43013683
ISSN: 1946-6242
CID: 6075826
Clonal heterogeneity in human pancreatic ductal adenocarcinoma and its impact on tumor progression
Kalfakakou, Despoina; Cameron, Daniel C; Kawaler, Emily A; Tsuda, Motoyuki; Wang, Lidong; Su, Qi; Kim, Sungsik; Manolakos, Elektra; Jing, Xiaohong; Hajdu, Cristina; Tamayo, Dylan L; Shim, Yoona; Ackermann, Amanda; Weissinger, Daniel; Zimny, Hayley; Hernandez, Rosmel; Beier, Matthew; Dimartino, Dacia; Meyn, Peter; Rice, Kalina; Selvaraj, Shanmugapriya; Loomis, Cynthia; Heguy, Adriana; Lund, Amanda W; Carter, Hannah; Sears, Rosalie C; Welling, Theodore H; Dolgalev, Igor; Tsirigos, Aristotelis; Simeone, Diane M
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer characterized by profound desmoplasia and cellular heterogeneity, which cannot be fully resolved using traditional bulk sequencing approaches. To understand how this heterogeneity contributes to PDAC biology, we analyzed a large cohort of primary tumors (n = 62) profiled using single-cell RNA sequencing (443,451 single cells), including a subset of 11 tumors with matched spatial transcriptomics (53,236 spots), to map clonal, transcriptional and spatial diversity. Moreover, our sample set includes a unique cohort of matched samples from six tumors collected before and after treatment with chemotherapy. Our analysis revealed notable intratumoral heterogeneity, with multiple genetically distinct neoplastic clones coexisting within individual tumors. We observed clone-specific ligand-receptor programs that are modulated by genomic dosage: amplifications of ligands or receptors enriched corresponding interactions, while deletions suppressed them, with genetically encoded differences supported by spatial transcriptomics and multiplex immunofluorescence. Phylogenetic integration identified focal 8q24 (MYC) amplification as recurrently associated with classical-to-basal transitions occurring within tumor lineages at a frequency above chance; these transitions were accompanied by coordinated depletion of immune-response programs. Functional perturbation experiments in murine and primary human models showed that MYC knockdown reactivates classical transcriptional programs and restores immune-response pathways, supporting a role for MYC in maintaining a basal, immune-depleted state. Spatial analyses further revealed dispersed clones enriched for epithelial-to-mesenchymal transition activity and immune suppression, correlating with metastatic potential and colonization of lymph node niches. These dispersed clones shifted toward a basal phenotype, contributing to disease progression. Our findings highlight the critical role of clonal diversity, transcriptional plasticity and tumor microenvironment interactions in shaping human PDAC biology. This work provides a detailed view of the molecular and spatial heterogeneity of PDAC and offers potential avenues for therapeutic intervention targeting clonal evolution and the mechanisms driving metastasis.
PMID: 42869988
ISSN: 1546-1718
CID: 6075704
RAS inhibition limits oncogenic signaling and tumorigenesis in neuroblastoma regardless of RAS mutational status
Mintoo, Mubashir; Rajagopalan, Vinodh; Greathouse, Rachel; Nasarre, Cecile; Trebino, Tarah; Santana, Dianicha; Flores-Galvez, Kevin O; Ketavarapu, Gayatri; Koide, Akiko; Hood, Fiona E; Prior, Ian A; Philips, Mark R; Koide, Shohei; Chiu, Bill; O'Bryan, John P
UNLABELLED:Neuroblastoma (NBL) is a rare and aggressive pediatric malignancy with a 5-year survival rate of 40-50% for patients diagnosed with high-risk disease. NBLs arise in the sympathetic nervous system and causes 11% of all pediatric cancer deaths. MYCN amplification or overexpression drives 22% of NBL cases while deregulation of genes including c-MYC, ALK, PHOX2B, and LIN28B also plays a critical role in NBL initiation and progression. Although RAS proto-oncogenes are rarely mutated in primary NBL (< 2%), studies suggest that elevated RAS activity may contribute to NBL tumorigenesis and progression. Here, we explore targeted RAS inhibition as a potential therapeutic strategy for NBL. Using mutation-specific inhibitors of KRAS, we demonstrate the importance of mutant KRAS in NBL. Furthermore, using anti-RAS biologics and a pan RAS inhibitor, we also demonstrate the importance of wild type (WT) RAS activity in non-RAS mutant NBLs. Direct RAS inhibition decreases NBL cell proliferation, colony formation, and migration in vitro in NBL lines differing in MYCN and RAS mutation status. Furthermore, inhibition of WT RAS suppresses the growth of specific NBL lines in vivo. Our findings suggest that targeted RAS inhibition, even in the absence of RAS mutation, may represent a promising therapeutic approach for NBL patients. SUPPLEMENTARY INFORMATION/UNASSIGNED:The online version contains supplementary material available at https://doi.org/10.1038/s41598-026-63488-x.
PMCID:13719498
PMID: 43019139
ISSN: 2045-2322
CID: 6075888
RAS inhibition limits oncogenic signaling and tumorigenesis in neuroblastoma regardless of RAS mutational status
Mintoo, Mubashir; Rajagopalan, Vinodh; Greathouse, Rachel; Nasarre, Cecile; Trebino, Tarah; Santana, Dianicha; Flores-Galvez, Kevin O; Ketavarapu, Gayatri; Koide, Akiko; Hood, Fiona E; Prior, Ian A; Philips, Mark R; Koide, Shohei; Chiu, Bill; O'Bryan, John P
UNLABELLED:Neuroblastoma (NBL) is a rare and aggressive pediatric malignancy with a 5-year survival rate of 40-50% for patients diagnosed with high-risk disease. NBLs arise in the sympathetic nervous system and causes 11% of all pediatric cancer deaths. MYCN amplification or overexpression drives 22% of NBL cases while deregulation of genes including c-MYC, ALK, PHOX2B, and LIN28B also plays a critical role in NBL initiation and progression. Although RAS proto-oncogenes are rarely mutated in primary NBL (< 2%), studies suggest that elevated RAS activity may contribute to NBL tumorigenesis and progression. Here, we explore targeted RAS inhibition as a potential therapeutic strategy for NBL. Using mutation-specific inhibitors of KRAS, we demonstrate the importance of mutant KRAS in NBL. Furthermore, using anti-RAS biologics and a pan RAS inhibitor, we also demonstrate the importance of wild type (WT) RAS activity in non-RAS mutant NBLs. Direct RAS inhibition decreases NBL cell proliferation, colony formation, and migration in vitro in NBL lines differing in MYCN and RAS mutation status. Furthermore, inhibition of WT RAS suppresses the growth of specific NBL lines in vivo. Our findings suggest that targeted RAS inhibition, even in the absence of RAS mutation, may represent a promising therapeutic approach for NBL patients. SUPPLEMENTARY INFORMATION/UNASSIGNED:The online version contains supplementary material available at https://doi.org/10.1038/s41598-026-63488-x.
PMCID:13719498
PMID: 43019139
ISSN: 2045-2322
CID: 6075889
Dual inhibition of TNF-α and IL-1β signaling through BIG2 ameliorates osteoarthritis in mouse and primate models
Fu, Wenyu; Liu, Ronghan; Wo, Jin; Liu, Xin; Wang, Shuya; Song, Wenhao; Zhu, Haoran; Cui, Yazhou; Chen, Yuehong; Wang, Chao; Zhang, Lei; Schwarzkopf, Ran; Oh, Irvin; Wiznia, Daniel H; Sun, Guodong; Liu, Chuan-Ju
Osteoarthritis (OA), a leading cause of disability, is characterized by chronic low-grade inflammation and metabolic dysregulation in chondrocytes. TNF-α and IL-1β are key inflammatory drivers in OA pathogenesis, but clinical trials targeting them individually have been unsuccessful, highlighting the potential need for dual-targeting strategies. By screening a US Food and Drug Administration-approved drug library, we identified dabigatran, a thrombin inhibitor, as a potent dual suppressor of TNF-α and IL-1β signaling that restored chondrocyte metabolism. In preclinical OA models, including both mice and cynomolgus macaques, dabigatran attenuated cartilage degeneration, alleviated pain, and improved joint function. To elucidate the molecular mechanisms, we performed biochemical copurification coupled with mass spectrometry, identifying brefeldin A-inhibited guanine nucleotide-exchange protein 2 (BIG2) as a previously unknown dabigatran-binding target. Mechanistically, dabigatran binds to BIG2, promoting BIG2-dependent TNFR1 release to dampen TNF-α signaling while enhancing BIG2-mediated IL-1R1 degradation through the autophagy-lysosome pathway to limit IL-1β effects. These findings establish BIG2-mediated receptor trafficking and membrane dynamics as a regulatory node that concurrently inhibits TNF-α and IL-1β signaling, suggesting this pathway as a potential therapeutic strategy for OA.
PMID: 43013683
ISSN: 1946-6242
CID: 6075827
Hoxa10 governs lifelong skeletal stem cell maintenance and bone repair
Leclerc, Kevin; Sambon, Margaux; Weng, Raven; Suhardi, Vincentius Jeremy; Ramsukh, Malissa; Phadke, Rohan; Pack, Gabrielle; Rytel, Matthew; Zhong, Jack; Schaffler, Benjamin; Butron, Sergio; Morgani, Sophie M; Leucht, Philipp
Skeletal stem and progenitor cells (SSPCs) sustain bone homeostasis and regeneration throughout life, yet the transcriptional programs that preserve their identity remain poorly defined. Here we identify the distal Hox gene Hoxa10 as a cell-autonomous regulator of skeletal stem cell maintenance. Using inducible genetic deletion, lineage tracing, single-cell transcriptomics, and injury models, we show that loss of Hoxa10 leads to progressive depletion of SSPCs, impaired bone regeneration, and defective matrix organization. Mechanistically, Hoxa10 maintains the undifferentiated state of skeletal stem cells by restraining premature osteogenic, adipogenic, and chondrogenic commitment, while promoting collagen III production and collagen fiber alignment within regenerative niches. Hoxa10-dependent regulation of extracellular matrix composition is restricted to primitive progenitors and is uncoupled from osteoblast differentiation. Notably, transient depletion of distal Hox genes in primary human SSPCs recapitulates the murine defects in proliferation, self-renewal, and differentiation restraint. Together, these findings define a conserved Hox-dependent program that preserves skeletal stem cell identity and regenerative competence, revealing how developmental transcription factors are repurposed to sustain the adult skeleton across the life span.
PMCID:13733894
PMID: 42981418
ISSN: 2375-2548
CID: 6075467
CoFiSA: a cross-disease single-cell atlas for fibrotic skin conditions
Jiang, Shujun; Ke, Alison; Zhou, Manqi; Lin, Meng-Ju; Tong, Jie; Lu, Catherine P; Su, Chang
PMID: 42998755
ISSN: 1523-1747
CID: 6075525
Amyloid-mediated RNA uptake by sperm for embryonic delivery
Mallen, William S; Zabello, Nataliya; Brenner-Morton, Susan; Sidoli, Simone; Liang, Feng-Xia; Sall, Joseph; Yin, Jason; Mathews, Priyanka; Zhu, Mengmeng; Zhang, Guoan; Lee, Carolyn L; Liao, Ya-Cheng; Fitzpatrick, Anthony W P
Seminal fluid (SF) RNA is essential for embryonic development, but the mechanism by which extracellular RNA is transferred from SF to sperm remains unclear. Here, we identify a role for functional amyloid fibrils in SF that bind and traffic RNA to mammalian sperm and, upon fertilization, to the zygote. We show that highly cationic peptides in SF phase separate with RNA to form amyloid fibrils. Cryo-electron tomography (cryo-ET), volume electron microscopy (volume EM), and fluorescence live-cell imaging reveal that these amyloid fibrils are internalized by mammalian sperm. Furthermore, biophysical and in vitro fertilization (IVF) experiments show that amyloid-bound RNA reaches the zygote, where molecular chaperones can control RNA dissociation from amyloid fibrils. Our work uncovers a mechanism for RNA trafficking from SF to the zygote, establishing amyloid fibrils as potential tools for RNA delivery during fertilization.
PMID: 42933403
ISSN: 1097-4164
CID: 6074725
The endoplasmic reticulum resident molecular chaperone, GRP170, is required to maintain podocyte homeostasis and function
Porter, Aidan W; Marciszyn, Allison E; Vorndran, Hannah E; Iyer, Anuradha R; Kleyman, Thomas R; Fisher, Edward A; Tan, Roderick J; Brodsky, Jeffrey L; Buck, Teresa M
The glomerulus, a unique capillary network in the nephron, filters an entire blood volume approximately 300 times a day. Specialized epithelial cells known as podocytes form a critical component of the glomerular filtration barrier, and diseases linked to podocyte injury include minimal change disease, focal segmental glomerulosclerosis, and diabetic kidney disease. Because podocytes are terminally differentiated, their ability to respond to external stress is critical. One class of proteins, molecular chaperones, protects against cell stress by preventing protein misfolding, assisting in protein refolding, maintaining protein solubility, and modulating protein translation. We previously found that depletion of one such molecular chaperone, GRP170, in the renal tubule induces the unfolded stress response (UPR), a stress-responsive pathway originating in the endoplasmic reticulum (ER), and causes apoptosis and acute kidney injury in mice. Here we report on a new constitutive podocyte-specific GRP170 knockout mouse (GRP170Pd-/-). Surprisingly, GRP170Pd-/- mice were born healthy. Within a month, however, these mice exhibited profound glomerular injury manifesting as proteinuria, hypoalbuminemia, hyperlipidemia, and kidney injury. Concomitant with glomerular injury, we observed increased expression of the pro-apoptotic UPR target, CHOP, and altered ER morphology in podocytes. Our new model not only defines a protective role for GRP170 against glomerular injury but provides a new avenue to test the therapeutic potential of small molecule UPR modulators to treat glomerular diseases.
PMID: 42932913
ISSN: 1522-1466
CID: 6074724